Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation-Reference-Cited by-同舟云学术

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

Published:2022-04 Issue:4 Volume:28 Page:214.e1-214.e11
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Huang Alice,Cicin-Sain Caroline,Pasin Chloe,Epp Selina,Audigé Annette,Müller Nicolas J.,Nilsson Jakob,Bankova Andriyana,Wolfensberger Nathan,Vilinovszki Oliver^ORCID,Nair Gayathri,Hockl Philipp,Schanz Urs,Kouyos Roger D.,Hasse Barbara^ORCID,Zinkernagel Annelies S.,Trkola Alexandra,Manz Markus G.^ORCID,Abela Irene A.^ORCID,Müller Antonia M.S.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference34 articles.

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int/. Accessed November 8th 2021.

2. Swissmedic. Swissmedic grants authorisation for the COVID-19 vaccine from Moderna. Available at: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/new-medicines.html. Accessed August 1st 2021.

3. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study;Sharma;Lancet Haematol,2021

4. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study;Passamonti;Lancet Haematol,2020

5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med.2020;383:2603-2615.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection;mBio;2024-01-25

2. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101);2024-01-25

3. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy;Transplantation and Cellular Therapy;2024-01

4. Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant;2023-10-27

5. Impact of a booster dose on SARS-CoV2 mRNA vaccine-specific humoral-, B- and T cell immunity in pediatric stem cell transplant recipients;Frontiers in Immunology;2023-10-24